Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects 50 Years of Age and Older With Ragweed-Induced Rhinoconjunctivitis (Protocol No. P06081)

NCT00978029 is registered in ClinicalTrials.gov with ALK-Abelló A/S as lead sponsor.

NCT NCT00978029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00978029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects 50 Years of Age and Older With Ragweed-Induced Rhinoconjunctivitis (Protocol No. P06081)
Lead sponsor
ALK-Abelló A/S
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
February 28, 2010
Enrollment
203 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

allergy, conjunctivitis, rhinitis, rhinoconjunctivitis